GlassScriptPhysician profile
Richard B Martin
NPI 1225023914
$9,446.38
in general payments reported to CMS, 2019-2025
45 companies · $1,859 in 2025
The $1,859 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $639 · 2021: $821 · 2022: $1,161 · 2023: $2,075 · 2024: $2,254 · 2025: $1,859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,187.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,316.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $1,234.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $918.97 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $875.58 | 2019-2025 | |
| Amgen INC. | $847.30 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $808.75 | 2020-2025 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $804.20 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $454.52 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.69 | 2019-2024 | Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.29 | 2022-2025 | Jardiance, Synjardy, Ofev |
| Abbott Laboratories | $219.63 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $176.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Ojjaara |
| Exact Sciences Corporation | $133.07 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $127.63 | 2022-2024 | Quviviq |
| Alcon Vision LLC | $116.80 | 2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.